@article {117531,
	title = {Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial.},
	journal = {Acta haematologica},
	volume = {123},
	year = {2010},
	month = {2010},
	pages = {220-5},
	abstract = {<p>Patient-reported outcomes of once-daily oral deferasirox (Exjade) in iron-overloaded patients with beta-thalassemia not achieving successful chelation with prior deferoxamine and/or deferiprone were investigated in a prospective, open-label, 1-year, multicenter study in the Middle East (ESCALATOR). The initial dose of deferasirox was 20 mg/kg/day, with subsequent dose adjustments. At baseline and the end of study (EOS), patients (n = 237) completed a 5-point rating scale for treatment satisfaction and convenience, and recorded time lost to treatment. At EOS, 90.7\% of patients were {\textquoteright}satisfied{\textquoteright}/{\textquoteright}very satisfied{\textquoteright} with their iron chelation therapy (ICT) versus 23.2\% at baseline. 92.8\% (EOS) versus 21.5\% (baseline) of patients considered their therapy to be {\textquoteright}convenient{\textquoteright}/{\textquoteright}very convenient{\textquoteright}. Time lost to therapy for daily activities was substantially reduced (3.2 +/- 8.6 [mean +/- SD; EOS] vs. 30.1 +/- 44.2 [baseline] h/month). Patients reported greater satisfaction and convenience, and lower impact on daily activities, with deferasirox than with previous ICT. This may help improve adherence to lifelong ICT in iron-overloaded beta-thalassemia patients.</p>
},
	keywords = {Adolescent, Adult, Benzoates, beta-Thalassemia, Child, Child, Preschool, Female, Humans, Iron Chelating Agents, Iron Overload, Male, Middle East, Patient Satisfaction, Prospective Studies, Triazoles},
	issn = {1421-9662},
	doi = {10.1159/000313447},
	author = {Ali Taher and Abdullah Al Jefri and Mohsen Saleh Elalfy and Kusai Al Zir and Shahina Daar and Rofail, Diana and Baladi, Jean Fran{\c c}ois and Dany Habr and Ulrike Kriemler-Krahn and Amal El-Beshlawy}
}
